Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation TCT 2025

TCT 1285: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): 5-year follow-up of a randomized controlled trial

Presenter: Lei Song

October 27, 2025

Presentation TCT 2025

TCT 408: Quantitative Flow Ratio-Guided Percutaneous Coronary Intervention Stratified by Coronary Territories: a Prespecified Subgroup Analysis of the FAVOR III China Trial

Presenter: Lei Song

October 26, 2025

Presentation TCT 2025

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

Presenter: Kyung Woo Park

October 26, 2025

Presentation TCT 2025

QFR vs. FFR for Coronary Revascularization Guidance: 2-Year Follow-up of the FAVOR III Europe Trial

Presenter: Birgitte Krogsgaard Andersen

October 25, 2025

Presentation TCT 2024

TCT 218: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention in Patients With and Without Multivessel Disease: A Pre-Specified Substudy From the FAVOR III China Trial

Presenter: han zhang

October 29, 2024

Presentation TCT 2024

TCT 18: The Impact of Coronary Physiology on the Initial Treatment Strategy for Percutaneous Coronary Intervention: Insights From FAVOR III China Trial

Presenter: Hao-Yu Wang

October 29, 2024

Presentation TCT 2021

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

Presenter: Bo Xu

November 04, 2021

Session II: Clinical Research and Practice in Percutaneous Coronary Intervention - Angiography-Based Physiological Lesion Assessment: QFR System and the FAVOR Trials

Presentation TCT 2019

Angiography-Based Physiological Lesion Assessment: QFR System and the FAVOR Trials

Presenter: Bo Xu

September 25, 2019

Presentation CIT 2019

The QFR System and the FAVOR Trials

Presenter: Bo Xu

March 28, 2019

Presentation CIT 2018

QFR (Quantitative Flow Reserve)A New Tool in Cathlab

Presenter: Shengxian Tu

March 23, 2018

Presentation TVT 2016

Study Design for the PARTNER 3 Low-Risk Trial

Presenter: Martin B. Leon

June 16, 2016

Presentation TVT 2016

Study Design for the EVOLUT R Low-Risk Trial

Presenter: Jeffrey J. Popma

June 16, 2016

Presentation TVT 2016

Updates From NOTION: The First All-Comer TAVR Trial

Presenter: Lars Sondergaard

June 16, 2016

Presentation TCT 2014

No: The Totality of Data Still Favors Aspiration, and TOTAL will Prove it!

Presenter: Vladimir Dzavik

September 14, 2014

Presentation TCT 2014

The Trial Got it So Wrong; For So Many Reasons: Repair Should Still Be Favored in Functional MR!

Presenter: Steven F. Bolling

September 14, 2014

Presentation TCT 2014

The Trial Got it Right: Replacement Is Favored in Functional MR!

Presenter: Michael J. Mack

September 14, 2014

Advertisement

TCT 1285: Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): 5-year follow-up of a randomized controlled trial

TCT 408: Quantitative Flow Ratio-Guided Percutaneous Coronary Intervention Stratified by Coronary Territories: a Prespecified Subgroup Analysis of the FAVOR III China Trial

Recent Coronary Trials: Role of Physiology - Put the Brakes On! (FAME 3; FAVOR 3; FLOWER MI)

QFR vs. FFR for Coronary Revascularization Guidance: 2-Year Follow-up of the FAVOR III Europe Trial

TCT 218: Angiographic Quantitative Flow Ratio-Guided Coronary Intervention in Patients With and Without Multivessel Disease: A Pre-Specified Substudy From the FAVOR III China Trial

TCT 18: The Impact of Coronary Physiology on the Initial Treatment Strategy for Percutaneous Coronary Intervention: Insights From FAVOR III China Trial

FAVOR III China: A Sham-Controlled Randomized Trial Comparing QFR-Guided and Angiography-Guided PCI

Angiography-Based Physiological Lesion Assessment: QFR System and the FAVOR Trials

The QFR System and the FAVOR Trials

QFR (Quantitative Flow Reserve)A New Tool in Cathlab

Study Design for the PARTNER 3 Low-Risk Trial

Study Design for the EVOLUT R Low-Risk Trial

Updates From NOTION: The First All-Comer TAVR Trial

No: The Totality of Data Still Favors Aspiration, and TOTAL will Prove it!

The Trial Got it So Wrong; For So Many Reasons: Repair Should Still Be Favored in Functional MR!

The Trial Got it Right: Replacement Is Favored in Functional MR!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content